Table 4.
Comparison of moderate and good EULAR response (weighted cohort) at 6, 12, and 24 months
| Follow-up time | No (%) | Odds ratio (95% CI) | |||||
|---|---|---|---|---|---|---|---|
| Rituximab | Abatacept | Tocilizumab | ABA v RTX | TOC v RTX | ABA v TOC | ||
| 6 months | 511 (54.5) | 235 (48.0) | 508 (72.9) | 0.77 (0.55 to 1.07) | 2.26 (1.51 to 3.37) | 0.34 (0.21 to 0.54) | |
| 12 months | 377 (43.3) | 171 (34.0) | 417 (59.9) | 0.66 (0.52 to 0.84) | 1.98 (1.30 to 3.03) | 0.33 (0.22 to 0.51) | |
| 24 months | 322 (34.6) | 125 (22.7) | 272 (44.2) | 0.55 (0.39 to 0.78) | 1.51 (0.95 to 2.41) | 0.37 (0.21 to 0.63) | |
EULAR=European League Against Rheumatism; ABA=abatacept; RTX=rituximab; TOC=tocilizumab.
Weighted cohort, pseudo-population obtained after inverse probability weighting.
EULAR non-response was considered death, discontinuation of the drug studied in the registry and/or initiation of a combination of conventional disease-modifying antirheumatic drugs and/or a new biologic and/or increase in oral corticosteroids dose >10 mg/day at 2 consecutive visits.